サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1773974

アミノグリコシドの世界市場

Aminoglycosides

出版日
ページ情報
英文 402 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
アミノグリコシドの世界市場
出版日: 2025年07月22日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 402 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アミノグリコシドの世界市場は2030年までに20億米ドルに到達

2024年に17億米ドルと推定されるアミノグリコシドの世界市場は、2024年から2030年にかけてCAGR 2.4%で成長し、2030年には20億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるネオマイシンアミノグリコシドは、CAGR 3.1%を記録し、分析期間終了時には4億3,050万米ドルに達すると予測されています。トブラマイシンアミノグリコシドセグメントの成長率は、分析期間中CAGR 2.5%と推定されます。

米国市場は4億7,570万米ドルと推定、中国はCAGR 4.7％で成長予測

米国のアミノグリコシド市場は、2024年に4億7,570万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを4.7%として、2030年までに3億8,580万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8%と1.8%と予測されています。欧州では、ドイツがCAGR 1.3%で成長すると予測されています。

世界のアミノグリコシド市場- 主要動向と促進要因のまとめ

なぜアミノグリコシドは現代医療に不可欠なのか？

アミノグリコシドは、特にグラム陰性菌によって引き起こされる重度の細菌感染に対する有効性のために広く使用されている、抗生物質の重要なクラスであり続けています。これらの殺菌剤は、細菌のリボソームに結合してタンパク質合成を阻害し、最終的に細胞死に導くことで機能します。代替抗生物質の出現にもかかわらず、アミノグリコシドは院内感染、敗血症、多剤耐性（MDR）菌の治療に重要な役割を果たし続けています。幅広いスペクトラム活性と迅速な殺菌効果により、集中治療や外科手術の予防に欠かせない存在となっています。さらに、ゲンタマイシン、アミカシン、トブラマイシンなどのアミノグリコシドは、特に併用療法において、呼吸器感染症、尿路感染症、結核によく処方されています。現在進行中の抗菌薬耐性（AMR）の増加は、逆説的にアミノグリコシドの重要性を高めています。製薬会社や研究機関もアミノグリコシドを再検討し、有効性を向上させ、長期使用に伴う最も一般的な副作用である腎毒性と耳毒性を軽減した新規誘導体を開発しています。アミノグリコシドの需要は、家畜、家禽、水産養殖の細菌感染症の治療に使用され、食の安全と動物の健康を確保している獣医学での広範な使用によって、さらに高まっています。

ドラッグフォーミュレーションとデリバリーシステムの進歩は、アミノグリコシドの使用をどのように促進しているか？

ドラッグの製剤化とデリバリー・システムの技術的進歩は、副作用を最小限に抑えながら有効性を高め、アミノグリコシド市場を大きく変えつつあります。従来のアミノグリコシドは、腎臓や内耳組織への蓄積による腎毒性や耳毒性があり、長期間の使用が制限されていました。しかし、リポソーム製剤、ナノ粒子ベースのデリバリー、徐放性注射システムなどの革新的なドラッグデリバリー機構は、薬物のターゲティングを改善し、全身毒性を軽減することにより、これらの限界に対処しています。例えばリポソーム製剤は、薬物を脂質小胞に封入することで薬物動態を改善し、組織への浸透性を高めて治療効果を持続させることができます。さらに、嚢胞性線維症患者用のトブラマイシン吸入ソリューションのような吸入可能なアミノグリコシドの台頭は、標的薬物デリバリーの新たな道を開き、全身への曝露を減らし、患者のコンプライアンスを向上させています。治療薬物モニタリング（TDM）や薬物動態／薬力学（PK／PD）モデリングを含む精密医療アプローチの統合は、アミノグリコシドの投与をさらに最適化し、毒性リスクを最小限に抑えながら最大限の有効性を確保しています。もう一つの有望な開発は、耐性メカニズムを克服し臨床的有用性を拡大するために、アミノグリコシドと他の抗菌剤を組み合わせたハイブリッド抗生物質のエンジニアリングです。これらの進歩は、アミノグリコシドの治療用途を拡大するだけでなく、安全性プロファイルを改善し、抗菌活性を強化した次世代誘導体に関する新たな研究をも推進しています。

アミノグリコシドの世界の需要を形成している市場動向は？

世界のアミノグリコシド市場は、規制政策、新興感染症、抗菌薬耐性（AMR）に対する懸念の高まりによってダイナミックな変化を経験しています。FDAやEMAなどの規制当局は、抗生物質の使用を積極的に監視し、耐性菌の発生や副作用を軽減するためにアミノグリコシドの投与に厳しいガイドラインを課しています。こうした規制を受けて、製薬会社は耐性菌に対する有効性を高めた新規アミノグリコシド誘導体の開発に投資しています。多剤耐性結核（MDR-TB）の蔓延も市場の成長に寄与しており、ストレプトマイシンやアミカシンなどのアミノグリコシドは、依然として第二選択治療レジメンの不可欠な構成要素となっています。さらに、畜産業や水産養殖業における効果的な抗生物質治療に対する需要が高まっていることから、獣医学分野も引き続きアミノグリコシドの重要な消費者となっています。しかし、食品中の抗生物質の残留や耐性開発への寄与に対する懸念の高まりから、規制機関は動物用抗生物質の使用に対してより厳格な規制を課すようになり、代替抗菌戦略の研究が活発化しています。市場はまた、治療効果を高めるためにβラクタム系抗生物質や他の相乗効果のある薬剤と組み合わせる併用療法への関心の高まりも目の当たりにしています。さらに、開発途上地域におけるヘルスケア・インフラの拡充は、特に資源が限られた環境における生命を脅かす細菌感染症に対するアミノグリコシド治療への幅広いアクセスを容易にしています。世界のヘルスケア政策が抗菌薬スチュワードシップと責任ある抗生物質使用を強調し続ける中、市場力学もそれに応じて進化していくと予想されます。

アミノグリコシド市場を促進する主な成長要因は？

アミノグリコシド市場の成長は、製薬研究の進歩、薬剤耐性細菌感染症の増加、ヒトおよび動物医療における用途の増加など、いくつかの要因によって牽引されています。リポソームカプセル化、ナノ粒子ベースのデリバリー、吸入療法など、ドラッグ製剤における絶え間ない技術革新は、アミノグリコシドの安全性と有効性を高め、長期使用に適しています。特に病院環境における多剤耐性グラム陰性感染症の蔓延が、最後の砦としてのアミノグリコシドの需要を牽引しており、代替療法の台頭にもかかわらず、アミノグリコシドの重要性が継続しています。獣医学では、集約的な畜産業と水産養殖業の拡大がアミノグリコシドの需要を押し上げているが、抗生物質の過剰使用に関する規制が長期的な市場動向に影響を与える可能性があります。さらに、製薬業界が併用療法やハイブリッド抗生物質の開発に注力することで、アミノグリコシドの応用範囲がさらに拡大し、より効果的に抗菌剤耐性と闘うのに役立っています。また、臨床現場における治療薬モニタリング（TDM）の採用拡大も、毒性リスクを最小限に抑えつつ有効性を最大化する個別化投与戦略を可能にするため、市場成長に寄与しています。さらに、新興市場、特にアジア太平洋、アフリカ、ラテンアメリカにおける投資の拡大は、アミノグリコシド治療への幅広いアクセスを促進し、感染症負担の大きい地域での市場拡大を促進しています。世界の保健機関が抗菌薬耐性の緩和を優先し続ける中、革新的なアミノグリコシド製剤や代替治療戦略への需要が高まり、今後数年間の市場の持続的成長が見込まれます。

セグメント

製品（ネオマイシンアミノグリコシド、トブラマイシンアミノグリコシド、アミカシンアミノグリコシド、カナマイシンアミノグリコシド、ストレプトマイシンアミノグリコシド、パロモマイシンアミノグリコシド、ゲンタマイシンアミノグリコシド、その他製品）、投与経路（注射剤投与経路、飼料投与経路、乳房内投与経路、局所投与経路、経口投与経路）、用途（呼吸器疾患用途、皮膚感染症用途、獣医用途、尿路結石および骨盤疾患用途、その他の用途）

調査対象企業の例

  • AdvaCare Pharma
  • Biofield Pharma Pvt Ltd
  • Tocris Bioscience
  • Canvax Reagents SL
  • Cipla LTd.
  • Fresenius Kabi USA, LLC
  • Glentham Life Sciences Ltd.
  • Hangzhou Longshine Bio-Tech Co., Ltd
  • Kremoint Pharma Pvt. Ltd
  • Pfizer, Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Vega Group Co., Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29131

Global Aminoglycosides Market to Reach US$2.0 Billion by 2030

The global market for Aminoglycosides estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2024-2030. Neomycin Aminoglycosides, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$430.5 Million by the end of the analysis period. Growth in the Tobramycin Aminoglycosides segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$475.7 Million While China is Forecast to Grow at 4.7% CAGR

The Aminoglycosides market in the U.S. is estimated at US$475.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$385.8 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Aminoglycosides Market - Key Trends & Drivers Summarized

Why Are Aminoglycosides Still Essential in Modern Medicine?

Aminoglycosides remain a crucial class of antibiotics, widely used for their efficacy against severe bacterial infections, particularly those caused by Gram-negative bacteria. These bactericidal agents function by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately leading to cell death. Despite the emergence of alternative antibiotics, aminoglycosides continue to play a vital role in treating hospital-acquired infections, septicemia, and multidrug-resistant (MDR) bacterial strains. Their broad-spectrum activity and rapid bactericidal effects make them indispensable in intensive care settings and surgical prophylaxis. Additionally, aminoglycosides such as gentamicin, amikacin, and tobramycin are commonly prescribed for respiratory tract infections, urinary tract infections, and tuberculosis, particularly in combination therapies. The ongoing rise in antimicrobial resistance (AMR) has paradoxically reinforced the relevance of aminoglycosides, as they remain effective against pathogens that have developed resistance to other antibiotic classes. Pharmaceutical companies and research institutions are also revisiting aminoglycosides to develop novel derivatives with improved efficacy and reduced nephrotoxicity and ototoxicity, the two most common side effects associated with prolonged use. The demand for aminoglycosides is further fueled by their extensive use in veterinary medicine, where they are employed to treat bacterial infections in livestock, poultry, and aquaculture, ensuring food safety and animal health.

How Are Advancements in Drug Formulation and Delivery Systems Enhancing Aminoglycoside Use?

Technological advancements in drug formulation and delivery systems are significantly transforming the aminoglycosides market, enhancing their efficacy while minimizing adverse effects. Conventional aminoglycosides have been associated with nephrotoxicity and ototoxicity due to their accumulation in renal and inner ear tissues, limiting their prolonged use. However, innovative drug delivery mechanisms such as liposomal formulations, nanoparticle-based delivery, and sustained-release injectable systems are addressing these limitations by improving drug targeting and reducing systemic toxicity. Liposomal aminoglycosides, for example, offer improved pharmacokinetics by encapsulating the drug in lipid vesicles, allowing for better tissue penetration and prolonged therapeutic effects. Additionally, the rise of inhalable aminoglycosides, such as tobramycin inhalation solutions for cystic fibrosis patients, has opened new avenues for targeted drug delivery, reducing systemic exposure and enhancing patient compliance. The integration of precision medicine approaches, including therapeutic drug monitoring (TDM) and pharmacokinetic/pharmacodynamic (PK/PD) modeling, is further optimizing aminoglycoside dosing, ensuring maximum efficacy while minimizing toxicity risks. Another promising development is the engineering of hybrid antibiotics that combine aminoglycosides with other antimicrobial agents to overcome resistance mechanisms and broaden their clinical utility. These advancements are not only extending the therapeutic applications of aminoglycosides but also driving new research into next-generation derivatives with improved safety profiles and enhanced antimicrobial activity.

What Market Trends Are Shaping the Global Demand for Aminoglycosides?

The global aminoglycosides market is experiencing dynamic shifts driven by regulatory policies, emerging infectious diseases, and growing concerns over antimicrobial resistance (AMR). Regulatory authorities such as the FDA and EMA are actively monitoring antibiotic usage, imposing stringent guidelines on aminoglycoside administration to mitigate resistance development and adverse effects. In response to these regulations, pharmaceutical companies are investing in the development of novel aminoglycoside derivatives with enhanced efficacy against resistant bacteria. The increasing prevalence of multidrug-resistant tuberculosis (MDR-TB) is also contributing to market growth, as aminoglycosides such as streptomycin and amikacin remain integral components of second-line treatment regimens. Additionally, the veterinary sector continues to be a significant consumer of aminoglycosides, with rising demand for effective antibiotic treatments in livestock farming and aquaculture industries. However, growing concerns over antibiotic residues in food products and their contribution to resistance development are prompting regulatory bodies to impose stricter controls on veterinary antibiotic use, leading to increased research on alternative antimicrobial strategies. The market is also witnessing rising interest in combination therapies, where aminoglycosides are paired with beta-lactam antibiotics or other synergistic agents to enhance their therapeutic effects. Moreover, the expansion of healthcare infrastructure in developing regions is facilitating wider access to aminoglycoside treatments, particularly for life-threatening bacterial infections in resource-limited settings. As global healthcare policies continue to emphasize antimicrobial stewardship and responsible antibiotic use, the market dynamics of aminoglycosides are expected to evolve accordingly.

What Are the Key Growth Drivers Fueling the Aminoglycosides Market?

The growth in the aminoglycosides market is driven by several factors, including advancements in pharmaceutical research, the rising burden of drug-resistant bacterial infections, and increasing applications in both human and veterinary medicine. The continuous innovation in drug formulation, including liposomal encapsulation, nanoparticle-based delivery, and inhalation therapies, is enhancing the safety and efficacy of aminoglycosides, making them more suitable for long-term use. The growing prevalence of multidrug-resistant Gram-negative infections, particularly in hospital settings, is driving the demand for aminoglycosides as last-resort antibiotics, ensuring their continued relevance despite the rise of alternative therapies. In veterinary medicine, the expansion of intensive livestock farming and aquaculture industries is boosting the demand for aminoglycosides, although regulatory restrictions on antibiotic overuse may impact long-term market trends. Additionally, the pharmaceutical industry’s focus on combination therapies and hybrid antibiotic development is further expanding the scope of aminoglycoside applications, helping to combat antimicrobial resistance more effectively. The increasing adoption of therapeutic drug monitoring (TDM) in clinical practice is also contributing to market growth, as it enables personalized dosing strategies that maximize efficacy while minimizing toxicity risks. Furthermore, growing investments in emerging markets, particularly in Asia-Pacific, Africa, and Latin America, are facilitating broader access to aminoglycoside treatments, driving market expansion in regions with high infectious disease burdens. As global health organizations continue to prioritize antimicrobial resistance mitigation, the demand for innovative aminoglycoside formulations and alternative treatment strategies is expected to rise, ensuring sustained market growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Aminoglycosides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides, Other Products); Route of Administration (Injectables Route of Administration, Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration); Application (Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI and Pelvic Diseases Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AdvaCare Pharma
  • Biofield Pharma Pvt Ltd
  • Tocris Bioscience
  • Canvax Reagents SL
  • Cipla LTd.
  • Fresenius Kabi USA, LLC
  • Glentham Life Sciences Ltd.
  • Hangzhou Longshine Bio-Tech Co., Ltd
  • Kremoint Pharma Pvt. Ltd
  • Pfizer, Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Vega Group Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Aminoglycosides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Bacterial Infections and Antimicrobial Resistance Fuels Demand for Aminoglycoside Antibiotics
    • Increasing Use of Aminoglycosides in Veterinary Medicine Strengthens Market Growth
    • Advancements in Drug Delivery Technologies Improve the Efficacy and Safety of Aminoglycosides
    • Growing Incidence of Multidrug-Resistant (MDR) Infections Necessitates the Continued Use of Aminoglycoside Therapies
    • Regulatory Approvals and Ongoing Clinical Research Drive the Development of Next-Generation Aminoglycosides
    • Rising Adoption of Combination Therapies with Aminoglycosides Enhances Treatment Effectiveness
    • Expansion of Hospital and Intensive Care Unit (ICU) Facilities Increases Demand for Injectable Aminoglycosides
    • Challenges Related to Ototoxicity and Nephrotoxicity Encourage Research on Safer Formulations
    • Growing Pharmaceutical Investments in Novel Antibiotic Development Boost the Aminoglycoside Market
    • Increasing Demand for Aminoglycosides in Emerging Markets Expands Global Market Reach
    • Surging Production of Generic Aminoglycosides Lowers Costs and Improves Accessibility
    • Development of Inhalable Aminoglycoside Formulations for Cystic Fibrosis and Respiratory Infections Enhances Market Potential
    • Government Initiatives to Combat Antimicrobial Resistance (AMR) Influence Antibiotic Stewardship Strategies
    • Rising Prevalence of Tuberculosis (TB) and Other Mycobacterial Infections Spurs Demand for Aminoglycosides
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Aminoglycosides Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Neomycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Neomycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Neomycin Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Tobramycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Tobramycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Tobramycin Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Amikacin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Amikacin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Amikacin Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Kanamycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Kanamycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Kanamycin Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Streptomycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Streptomycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Streptomycin Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Paromomycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Paromomycin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Paromomycin Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Gentamicin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Gentamicin Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Gentamicin Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Feed Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Feed Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Feed Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Intra-mammary Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Intra-mammary Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Intra-mammary Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Topical Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Topical Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Topical Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Oral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Injectables Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Injectables Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Injectables Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Respiratory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Respiratory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Respiratory Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Skin Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Skin Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Skin Infection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Veterinary Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Veterinary Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Veterinary Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for UTI & Pelvic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for UTI & Pelvic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for UTI & Pelvic Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 59: USA Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: USA 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 86: China Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Aminoglycosides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 134: UK Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Spain 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Russia 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Russia 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 158: Russia Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Russia Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Russia 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Aminoglycosides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Australia 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Australia 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 188: Australia Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Australia Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Australia 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 191: India Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: India 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: India 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 197: India Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: India Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: India 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: South Korea 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: South Korea 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 206: South Korea Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: South Korea Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: South Korea 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Asia-Pacific Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Asia-Pacific 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Aminoglycosides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Latin America 15-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Latin America 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Latin America 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 227: Latin America Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Latin America Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Latin America 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Argentina 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Argentina 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 236: Argentina Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Argentina Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Argentina 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Brazil 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Brazil 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 245: Brazil Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Brazil Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Brazil 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Mexico 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Mexico 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 254: Mexico Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Mexico Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Mexico 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Latin America 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 263: Rest of Latin America Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Latin America Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Rest of Latin America 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Aminoglycosides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Aminoglycosides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Middle East 15-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Middle East 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Middle East 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 275: Middle East Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Middle East Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Middle East 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Iran 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Iran 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 284: Iran Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Iran Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Iran 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Israel 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Israel 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 293: Israel Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Israel Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Israel 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Saudi Arabia 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 302: Saudi Arabia Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Saudi Arabia Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Saudi Arabia 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: UAE 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: UAE 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 311: UAE Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: UAE Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: UAE 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Middle East 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 320: Rest of Middle East Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Middle East Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Rest of Middle East 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Aminoglycosides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Aminoglycosides by Product - Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Africa 15-Year Perspective for Aminoglycosides by Product - Percentage Breakdown of Value Sales for Neomycin Aminoglycosides, Tobramycin Aminoglycosides, Amikacin Aminoglycosides, Kanamycin Aminoglycosides, Streptomycin Aminoglycosides, Paromomycin Aminoglycosides, Gentamicin Aminoglycosides and Other Products for the Years 2015, 2025 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Aminoglycosides by Route Of Administration - Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Africa 15-Year Perspective for Aminoglycosides by Route Of Administration - Percentage Breakdown of Value Sales for Feed Route of Administration, Intra-mammary Route of Administration, Topical Route of Administration, Oral Route of Administration and Injectables Route of Administration for the Years 2015, 2025 & 2030
    • TABLE 329: Africa Recent Past, Current & Future Analysis for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Africa Historic Review for Aminoglycosides by Application - Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Africa 15-Year Perspective for Aminoglycosides by Application - Percentage Breakdown of Value Sales for Respiratory Diseases Application, Skin Infection Application, Veterinary Application, UTI & Pelvic Diseases Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION